Full text
| |
| Author(s): |
Marcela Custódio Scherr
Total Authors: 1
|
| Document type: | Master's Dissertation |
| Press: | Campinas, SP. |
| Institution: | Universidade Estadual de Campinas (UNICAMP). Faculdade de Ciências Médicas |
| Defense date: | 2010-03-16 |
| Examining board members: |
Carmen Silvia Passos Lima;
Mirela Tinucci Costa;
José Vassallo
|
| Advisor: | Carmen Silvia Passos Lima |
| Abstract | |
The ability to metabolize xenobiotics is variable among humans and dogs, and is related to the distinct genotypes of polymorphic genes. Carriers of the CYP1A2 1117TT genotype were classified as poor metabolizers of drugs. In addition, the varying T and C alleles of CYP1A2 C1117T e GSTA3 I71L polymorphisms were described as less efficient in the activation and inactivation of carcinogens than the wild alleles, respectively. Thus, humans and dogs seem to obtain distinct benefits under drug treatments and also to be under different risks of tumours. The frequencies of genotypes of the refered genes in dogs of different breeds and mixed breed are yet not described. The objective of this study was to identify the frequencies of the genotypes in 105 boxers, 84 rottweilers, 110 german shepherds and 99 mixed breed dogs with the purpose of to verify if a distinct distribution of genotypes occurs in animals of different groups.The genotypes were evaluated by amplifying the area of interest of the genes, in peripheral blood samples, using a polymerase chain reaction followed by a sequencing or enzymatic digestion of the amplified fragments. The frequency of the homozygous wild CC genotype of the CYP1A2 C1117 polymorphism was higher in dogs of pure breed (96,4% versus 87,9%, P= 0.002) and boxers (98.0% versus 87,9%, P= 0.005) than in mixed breed dogs. Similar frequencies of the genotypes were seem in dogs stratified by clinical features. Just the CC varying genotype of the GSTA3 I71L polymorphism was identified in all dogs. The results of this study suggest that pure breed dogs might be more efficient in metabolizing drugs and in activating carcinogens than mixed breed dogs, and therefore, may obtain larger therapeutic benefits under treatment for diseases and may be under higher risk for tumors. In contrast, the metabolim of xenobiotics by the GSTA3 enzyme seems to be similar among dogs of different breeds and not to influence on a different way the drug metabolism or tumour risk in these animals (AU) | |